Skip to main content

Neoadjuvant Carboplatin/Paclitaxel Showing Potential in Esophageal Cancer – See more at: http://global.onclive.com/conference-coverage/GI-2016/neoadjuvant-carboplatin-paclitaxel-showing-potential-in-esophageal-cancer#sthash.qAREGpau.dpuf

Neoadjuvant treatment with carboplatin and paclitaxel-based chemotherapy (CarPacRT) produced a 27.9% pathologic complete response (pCR) rate in patients with resectable esophageal cancer, according to results of the NEOSCOPE trial.
http://global.onclive.com/conference-coverage/GI-2016/neoadjuvant-carboplatin-paclitaxel-showing-potential-in-esophageal-cancer

AUDIENCES

SUBJECTS

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino